Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1617 1643 1645 1646
This examiner grants 63% of resolved cases
Lynn Anne Bristol is a patent examiner in Tech Center 1600 and Art Unit 1600. She has overseen 1157 resolved cases, providing a substantial dataset for practitioners to analyze. Her allowance rate of 63.4% serves as a primary indicator of the likelihood of securing a patent grant during prosecution. This 63.4% rate suggests the frequency with which applications in her docket reach a successful conclusion, offering a clear expectation for stakeholders in this technology area.
The interview lift of 39.8% is a notable metric for practitioners. This 39.8% figure indicates that conducting a formal interview with Bristol is associated with an increase in the probability of an application being allowed. Given this lift, attorneys may find that direct communication is an effective tool for resolving technical issues. Additionally, the median days to allowance is 1229. This 1229-day timeline provides a temporal benchmark for the prosecution cycle from filing to grant. The combination of 1157 resolved cases and the 1229-day median pendency offers a comprehensive view of the examiner's historical performance. Practitioners can use these data points to inform their strategy and manage client expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17910327 | AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2 | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED |
| 18210885 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Non-Final OA | GENENTECH, INC. |
| 17257391 | ANTIBODY TUMOR-TARGETING ASSEMBLY COMPLEXES | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18268840 | EFFECTORLESS FC MOLECULES | Final Rejection | SANOFI |
| 17481578 | SERUM ALBUMIN-BINDING IMMUNOGLOBULIN VARIABLE DOMAINS | Non-Final OA | Sanofi |
| 17914432 | METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18600323 | ANTI-TIM3 ANTIBODIES AND METHODS OF USE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17937440 | BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT | Non-Final OA | Hoffmann-La Roche Inc. |
| 17907781 | SELECTIVE MODULATION OF TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY SIGNALING VIA MULTI-SPECIFIC ANTIBODIES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18538279 | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 | Non-Final OA | AMGEN INC. |
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | Final Rejection | AMGEN INC. |
| 16869793 | DOSING REGIMEN FOR ANTI-BCMA AGENTS | Non-Final OA | AMGEN INC. |
| 18365239 | FUSION PROTEIN BASED ON SINGLE-CHAIN ANTIBODY FRAGMENT, NANO-ASSEMBLY, AND PREPARATION METHODS THEREFOR AND APPLICATIONS THEREOF | Final Rejection | SOUTH CHINA UNIVERSITY OF TECHNOLOGY |
| 18474824 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18501782 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | Non-Final OA | MedImmune, LLC |
| 17907683 | STABILIZED IGG4 ANTIBODIES AND USES THEREOF | Non-Final OA | MEDIMMUNE, LLC |
| 18284009 | TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | Non-Final OA | MERUS N.V. |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | Non-Final OA | Merus N.V. |
| 18027583 | EGFR BINDING COMPLEX AND METHOD OF MAKING AND USING THEREOF | Final Rejection | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 18056648 | CYTOKINE VARIANT ANTIBODIES AND METHODS OF USE | Final Rejection | Twist Bioscience Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy